Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Thrombocytopenia 1Myelodysplastic Syndromes 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 21fludarabine phosphate 15Cyclosporine 13Antilymphocyte Serum 13Peripheral Blood Stem Cell Transplantation 12Busulfan 12Whole-Body Irradiation 11Mycophenolic Acid 10Filgrastim 8fludarabine 7Methotrexate 7Melphalan 7Therapeutics 5Radiotherapy 5Cytarabine 5Blood Specimen Collection 5Tacrolimus 4Psychiatric Rehabilitation 4Methylprednisolone 4Cord Blood Stem Cell Transplantation 4thymoglobulin 3Stem Cell Transplantation 3Palliative Care 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Dexamethasone 3Behavior Therapy 3Aprepitant 3sargramostim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Platelet Transfusion × Myeloid × Clear all
NCT01615146 2015-09-02

OPTIMAL

Ottawa Hospital Research Institute

Phase NA Terminated
9 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡